Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients

缓解非裔美国人和其他癌症患者的 EGFR 抑制剂皮疹

基本信息

  • 批准号:
    9274475
  • 负责人:
  • 金额:
    $ 38.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-04-01 至 2022-03-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Epidermal growth factor receptor (EGFR) inhibitors comprise a commonly prescribed class of drug that improves survival in patients with a variety of malignancies. Rash, particularly on the face, is the most common adverse event and occurs in 50-90% of patients, is severe in 10-20% of patients, lacks effective palliative options, and sometimes requires stopping cancer therapy. We have published qualitative research from patients who developed this rash and learned that it leads to cutaneous pain, psychological distress, and social isolation. One patient stated, "My face looks so bad that if I go see my friends, they say, 'What happened to you.' I am self-conscious about that." Another commented, “I just told them they would be better off just calling me, don't come visit.” Another described, "I can feel the itch and burn all over." Some investigators have suggested that African American patients do not suffer these symptoms. Here, we hypothesize that they do, that their pigmented skin might camoflage the rash, but that this rash still causes them physical and psychological pain. Building on our data (a 933-patient epidemiologic study that shows rash is worse in men; pilot clinical trial data that show benefit with a topical anti-androgen; and an androgen-dependent gene profile from skin biopsies from patients with EGFR inhibitor rash) and on data from others (some melanocytes overexpress androgens and androgen receptors), we hypothesize this rash is androgen-driven and that the topical antiandrogen, ketoconazole, palliates it in all patients, including African American cancer patients. In Aim #1, we will interview African American patients who have developed this rash and will use novel qualitative methods to probe into their hypothesized psychological and cutaneous distress. In Aim #2, we will conduct a randomized, double-blinded, placebo-controlled trial with ketoconazole (a topical anti- androgen) to determine whether this agent palliates rash within a racially diverse cohort and to explore whether it does so by modulating androgen-dependent genes, as alluded to above. The long-term goal of this line of investigation is to reduce suffering and improve the quality of life of all patients -- including African American patients -- who suffer from EGFR inhibitor-induced rash.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Aminah Jatoi其他文献

Aminah Jatoi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Aminah Jatoi', 18)}}的其他基金

Older Sexual and Gender Minority Patients with Serious Illness: Program-Building to Identify and Address Needs
患有严重疾病的老年性和性别少数患者:建立项目以确定和满足需求
  • 批准号:
    10684915
  • 财政年份:
    2022
  • 资助金额:
    $ 38.53万
  • 项目类别:
Older Sexual and Gender Minority Patients with Serious Illness: Program-Building to Identify and Address Needs
患有严重疾病的老年性和性别少数患者:建立项目以确定和满足需求
  • 批准号:
    10523705
  • 财政年份:
    2022
  • 资助金额:
    $ 38.53万
  • 项目类别:
Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients
缓解非裔美国人和其他癌症患者的 EGFR 抑制剂皮疹
  • 批准号:
    10599238
  • 财政年份:
    2017
  • 资助金额:
    $ 38.53万
  • 项目类别:
Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients
缓解非裔美国人和其他癌症患者的 EGFR 抑制剂皮疹
  • 批准号:
    9934138
  • 财政年份:
    2017
  • 资助金额:
    $ 38.53万
  • 项目类别:
Palliating EGFR Inhibitor Rash in African American and Other Cancer Patients
缓解非裔美国人和其他癌症患者的 EGFR 抑制剂皮疹
  • 批准号:
    10381450
  • 财政年份:
    2017
  • 资助金额:
    $ 38.53万
  • 项目类别:
Mentoring and Research in Cancer Palliative Care
癌症姑息治疗的指导和研究
  • 批准号:
    8312330
  • 财政年份:
    2008
  • 资助金额:
    $ 38.53万
  • 项目类别:
Rash from EGFR Inhibitors: Characterization & Palliation of a Symptom Cluster
EGFR 抑制剂引起的皮疹:特征
  • 批准号:
    7503895
  • 财政年份:
    2008
  • 资助金额:
    $ 38.53万
  • 项目类别:
Rash from EGFR Inhibitors: Characterization & Palliation of a Symptom Cluster
EGFR 抑制剂引起的皮疹:特征
  • 批准号:
    7666950
  • 财政年份:
    2008
  • 资助金额:
    $ 38.53万
  • 项目类别:
Mentoring and Research in Cancer Palliative Care
癌症姑息治疗的指导和研究
  • 批准号:
    8126204
  • 财政年份:
    2008
  • 资助金额:
    $ 38.53万
  • 项目类别:
Mentoring and Research in Cancer Palliative Care
癌症姑息治疗的指导和研究
  • 批准号:
    7525230
  • 财政年份:
    2008
  • 资助金额:
    $ 38.53万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 38.53万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 38.53万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 38.53万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 38.53万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 38.53万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 38.53万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 38.53万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 38.53万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 38.53万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 38.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了